Innovex International vs NOV
INVX and NOV side by side, both in construction, mining, and materials handling. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INVX and NOV compare
NOV is the larger company, worth 3.6 times as much as Innovex International ($6.4B against $1.8B).
On earnings, Innovex International is cheaper: it trades at 36.7× trailing earnings, against 45.2× for NOV.
Innovex International grew revenue faster over the last twelve months (7.0% versus −0.98% for NOV).
Innovex International keeps more of each dollar of sales as profit, with a net margin of 4.8% compared with 1.6% at NOV.
NOV pays a dividend yielding 2.4%; Innovex International does not pay one.
NOV scores higher on the StockData Score (10 against 9 for Innovex International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INVX | NOV |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $6.4B |
| Share price | $25.30 | $18.09 |
| Change, 1 year | 25.1% | 17.5% |
| Change, 5 years | 29.9% | 50.4% |
| Beta (5Y) | 0.86 | 0.82 |
| Employees | 2,160 | 35K |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 36.7× (better) | 45.2× |
| P/S | 1.7× | 0.7× (better) |
| P/B | 1.6× | 1.0× (better) |
| EV/EBITDA | 11.9× | 8.5× (better) |
| P/FCF | – | 23.9× |
| FCF yield | – | 4.2% |
| Fair value | $19.93 | $16.12 |
| Margin of safety | −27.0% | −12.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 7.0% (better) | −0.98% |
| Revenue growth, 5Y average | 21.8% (better) | 7.5% |
| Net income growth (TTM) | −51.9% (better) | −62.7% |
| EPS growth (TTM) | −48.1% (better) | −60.0% |
| Profitability | ||
| Gross margin | 33.6% (better) | 20.7% |
| Operating margin | 6.9% (better) | 5.5% |
| Net margin | 4.8% (better) | 1.6% |
| FCF margin | – | 3.1% |
| Return on equity | 4.5% (better) | 2.3% |
| Return on invested capital | 4.9% (better) | 3.4% |
| Financial health | ||
| Debt / equity | 0.02 (better) | 0.27 |
| Net debt / EBITDA | −1.22 | 0.77 (better) |
| Interest coverage | 19.1× (better) | 5.5× |
| Current ratio | 4.43 (better) | 2.51 |
| Altman Z-score | 5.29 (better) | 2.00 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 2.4% |
| Payout ratio | – | 109% |
| Years of dividend growth | – | 2 |
| Dividend growth, 5Y average | – | 59.1% |
| Buyback yield | 0.80% | 3.6% (better) |
| Shareholder yield | 0.80% | 6.0% (better) |
| Ownership | ||
| Held by institutions | 73.5% | 109% |
| Held by insiders | – | 1.2% |
| Insider net buying, 12 months | −$615M | −$4.6M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 7.8% |
Go deeper
- INVX stock overview
- INVX income statement
- INVX valuation and score
- NOV stock overview
- NOV income statement
- NOV valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.